These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 12362748)
1. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments]. Liedholm H; Linné AB Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748 [TBL] [Abstract][Full Text] [Related]
2. Equivalence trials: methodologic analysis. Carneiro A Rev Port Cardiol; 2003 Sep; 22(9):1125-39. PubMed ID: 14655314 [TBL] [Abstract][Full Text] [Related]
4. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
5. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents? Antman EM; Ferguson JJ Circulation; 2003 Nov; 108(21):2604-7. PubMed ID: 14638523 [No Abstract] [Full Text] [Related]
6. [Methodological and statistical aspects of equivalence and non inferiority trials]. Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296 [TBL] [Abstract][Full Text] [Related]
7. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"? Furberg CD; Psaty BM Circulation; 2003 Nov; 108(21):2608-10. PubMed ID: 14638524 [No Abstract] [Full Text] [Related]
8. [Class substitution as an instrument of efficiency in the supply of medicines: possibilities and limitations]. de Smet PA; van der Kuy A; Bonsel GJ Ned Tijdschr Geneeskd; 2002 Mar; 146(12):553-7. PubMed ID: 11938577 [TBL] [Abstract][Full Text] [Related]
9. Multinational medicines--ensuring drug quality in an era of global manufacturing. Okie S N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686 [No Abstract] [Full Text] [Related]
10. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
11. Drug class effects: definitions and practical applications. Soares I; Carneiro AV Rev Port Cardiol; 2002 Sep; 21(9):1031-42. PubMed ID: 12416274 [TBL] [Abstract][Full Text] [Related]
12. [Follow up studies as a condition for drug subsidizing]. Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842 [No Abstract] [Full Text] [Related]
13. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. Wehling M J Am Geriatr Soc; 2009 Mar; 57(3):560-1. PubMed ID: 19278399 [No Abstract] [Full Text] [Related]